These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

227 related articles for article (PubMed ID: 38427495)

  • 1. Mono- and Biallelic Inactivation of Huntingtin Gene in Patient-Specific Induced Pluripotent Stem Cells Reveal HTT Roles in Striatal Development and Neuronal Functions.
    Louessard M; Cailleret M; Jarrige M; Bigarreau J; Lenoir S; Dufour N; Rey M; Saudou F; Deglon N; Perrier AL
    J Huntingtons Dis; 2024; 13(1):41-53. PubMed ID: 38427495
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Loss of huntingtin function slows synaptic vesicle endocytosis in striatal neurons from the htt
    McAdam RL; Morton A; Gordon SL; Alterman JF; Khvorova A; Cousin MA; Smillie KJ
    Neurobiol Dis; 2020 Feb; 134():104637. PubMed ID: 31614197
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Energy Metabolism and Mitochondrial Superoxide Anion Production in Pre-symptomatic Striatal Neurons Derived from Human-Induced Pluripotent Stem Cells Expressing Mutant Huntingtin.
    Hamilton J; Brustovetsky T; Sridhar A; Pan Y; Cummins TR; Meyer JS; Brustovetsky N
    Mol Neurobiol; 2020 Feb; 57(2):668-684. PubMed ID: 31435904
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Human Huntington's disease pluripotent stem cell-derived microglia develop normally but are abnormally hyper-reactive and release elevated levels of reactive oxygen species.
    O'Regan GC; Farag SH; Casey CS; Wood-Kaczmar A; Pocock JM; Tabrizi SJ; Andre R
    J Neuroinflammation; 2021 Apr; 18(1):94. PubMed ID: 33874957
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Loss-of-Huntingtin in Medial and Lateral Ganglionic Lineages Differentially Disrupts Regional Interneuron and Projection Neuron Subtypes and Promotes Huntington's Disease-Associated Behavioral, Cellular, and Pathological Hallmarks.
    Mehler MF; Petronglo JR; Arteaga-Bracho EE; Gulinello ME; Winchester ML; Pichamoorthy N; Young SK; DeJesus CD; Ishtiaq H; Gokhan S; Molero AE
    J Neurosci; 2019 Mar; 39(10):1892-1909. PubMed ID: 30626701
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Progerin-Induced Transcriptional Changes in Huntington's Disease Human Pluripotent Stem Cell-Derived Neurons.
    Cohen-Carmon D; Sorek M; Lerner V; Divya MS; Nissim-Rafinia M; Yarom Y; Meshorer E
    Mol Neurobiol; 2020 Mar; 57(3):1768-1777. PubMed ID: 31834602
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Excess Rab4 rescues synaptic and behavioral dysfunction caused by defective HTT-Rab4 axonal transport in Huntington's disease.
    White JA; Krzystek TJ; Hoffmar-Glennon H; Thant C; Zimmerman K; Iacobucci G; Vail J; Thurston L; Rahman S; Gunawardena S
    Acta Neuropathol Commun; 2020 Jul; 8(1):97. PubMed ID: 32611447
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Huntingtin lowering impairs the maturation and synchronized synaptic activity of human cortical neuronal networks derived from induced pluripotent stem cells.
    Louçã M; El Akrouti D; Lemesle A; Louessard M; Dufour N; Baroin C; de la Fouchardière A; Cotter L; Jean-Jacques H; Redeker V; Perrier AL
    Neurobiol Dis; 2024 Oct; 200():106630. PubMed ID: 39106928
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Striatal Mutant Huntingtin Protein Levels Decline with Age in Homozygous Huntington's Disease Knock-In Mouse Models.
    Franich NR; Basso M; André EA; Ochaba J; Kumar A; Thein S; Fote G; Kachemov M; Lau AL; Yeung SY; Osmand A; Zeitlin SO; Ratan RR; Thompson LM; Steffan JS
    J Huntingtons Dis; 2018; 7(2):137-150. PubMed ID: 29843246
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cellular Models: HD Patient-Derived Pluripotent Stem Cells.
    Geater C; Hernandez S; Thompson L; Mattis VB
    Methods Mol Biol; 2018; 1780():41-73. PubMed ID: 29856014
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Full length mutant huntingtin is required for altered Ca2+ signaling and apoptosis of striatal neurons in the YAC mouse model of Huntington's disease.
    Zhang H; Li Q; Graham RK; Slow E; Hayden MR; Bezprozvanny I
    Neurobiol Dis; 2008 Jul; 31(1):80-8. PubMed ID: 18502655
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Specific caspase interactions and amplification are involved in selective neuronal vulnerability in Huntington's disease.
    Hermel E; Gafni J; Propp SS; Leavitt BR; Wellington CL; Young JE; Hackam AS; Logvinova AV; Peel AL; Chen SF; Hook V; Singaraja R; Krajewski S; Goldsmith PC; Ellerby HM; Hayden MR; Bredesen DE; Ellerby LM
    Cell Death Differ; 2004 Apr; 11(4):424-38. PubMed ID: 14713958
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Generation of New Isogenic Models of Huntington's Disease Using CRISPR-Cas9 Technology.
    Dabrowska M; Ciolak A; Kozlowska E; Fiszer A; Olejniczak M
    Int J Mol Sci; 2020 Mar; 21(5):. PubMed ID: 32182692
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Poly ADP-ribose signaling is dysregulated in Huntington disease.
    Maiuri T; Bazan CB; Harding RJ; Begeja N; Kam TI; Byrne LM; Rodrigues FB; Warner MM; Neuman K; Mansoor M; Badiee M; Dasovich M; Wang K; Thompson LM; Leung AKL; Andres SN; Wild EJ; Dawson TM; Dawson VL; Arrowsmith CH; Truant R
    Proc Natl Acad Sci U S A; 2024 Oct; 121(40):e2318098121. PubMed ID: 39331414
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Modulating FKBP5/FKBP51 and autophagy lowers HTT (huntingtin) levels.
    Bailus BJ; Scheeler SM; Simons J; Sanchez MA; Tshilenge KT; Creus-Muncunill J; Naphade S; Lopez-Ramirez A; Zhang N; Lakshika Madushani K; Moroz S; Loureiro A; Schreiber KH; Hausch F; Kennedy BK; Ehrlich ME; Ellerby LM
    Autophagy; 2021 Dec; 17(12):4119-4140. PubMed ID: 34024231
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pridopidine protects neurons from mutant-huntingtin toxicity via the sigma-1 receptor.
    Eddings CR; Arbez N; Akimov S; Geva M; Hayden MR; Ross CA
    Neurobiol Dis; 2019 Sep; 129():118-129. PubMed ID: 31108174
    [TBL] [Abstract][Full Text] [Related]  

  • 17. N-terminal mutant huntingtin deposition correlates with CAG repeat length and symptom onset, but not neuronal loss in Huntington's disease.
    Layburn FE; Tan AYS; Mehrabi NF; Curtis MA; Tippett LJ; Turner CP; Riguet N; Aeschbach L; Lashuel HA; Dragunow M; Faull RLM; Singh-Bains MK
    Neurobiol Dis; 2022 Nov; 174():105884. PubMed ID: 36220612
    [TBL] [Abstract][Full Text] [Related]  

  • 18. FOXOs modulate proteasome activity in human-induced pluripotent stem cells of Huntington's disease and their derived neural cells.
    Liu Y; Qiao F; Leiferman PC; Ross A; Schlenker EH; Wang H
    Hum Mol Genet; 2017 Nov; 26(22):4416-4428. PubMed ID: 28973411
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cellular Analysis of Silencing the Huntington's Disease Gene Using AAV9 Mediated Delivery of Artificial Micro RNA into the Striatum of Q140/Q140 Mice.
    Keeler AM; Sapp E; Chase K; Sottosanti E; Danielson E; Pfister E; Stoica L; DiFiglia M; Aronin N; Sena-Esteves M
    J Huntingtons Dis; 2016 Oct; 5(3):239-248. PubMed ID: 27689620
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mutant Huntingtin alters retrograde transport of TrkB receptors in striatal dendrites.
    Liot G; Zala D; Pla P; Mottet G; Piel M; Saudou F
    J Neurosci; 2013 Apr; 33(15):6298-309. PubMed ID: 23575829
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.